Cadenza Bio Successful Secures $2.44 Million in Seed Funding
Cadenza Bio, a biotechnology firm located in Oklahoma City, has raised $2.44 million from an oversubscribed Seed fundraising round.
With the successful funding round led by Plains Ventures and supported by a group that included the Oklahoma Life Science Fund, Cortado Ventures, Boyd Street Ventures, and Illinois Ventures, the preclinical biotechnology firm has achieved a remarkable milestone. This accomplishment is a turning point in the company’s history and highlights the depth of trust and support received from a wide range of investors in a variety of industries.
The primary goal of Cadenza Bio is to develop unique small molecule medications for the treatment of demyelinating and inflammatory diseases, particularly Multiple Sclerosis (MS). This most recent funding boost will be used to progress non-clinical safety and toxicity studies, which are crucial to advancing CAD-1, the main development candidate, closer to clinical trials for multiple sclerosis. Additionally, the financing will facilitate studies into secondary indications, thereby enhancing the potential impact of this therapeutic strategy.
Drs. John Katzenellenbogen of the University of Illinois Urbana-Champaign (UIUC) and Seema Tiwari-Woodruff of the University of California, Riverside (UCR) collaborated to establish Cadenza Bio, which was founded in 2022. Ascend BioVentures in Oklahoma City and SmartHealth Catalyzer in Chicago initially partnered to develop the technology. This technology, partially funded by the National Multiple Sclerosis Society’s Fast Forward commercial research programme, presents fascinating possibilities for therapeutic intervention with its focus on Estrogen Receptor β (ERβ).
Multiple Sclerosis (MS) is a chronic autoimmune disease characterized by the immune system’s assault on the myelin sheath, leading to compromised nerve signaling and a myriad of incapacitating symptoms. The current state of treatment is inadequate to address nerve damage repair and functional restoration; most treatments target the underlying mechanisms of nerve regeneration and repair, but predominantly focus on immune suppression to slow the progression of the disease.
The CEO of Cadenza Bio, Dr. Carol Curtis, emphasized the company’s steadfast dedication to developing novel medicines and conveyed her sincere appreciation to the initial investors for their indispensable assistance. Together with co-founder Dr. Elaine Hamm, Curtis hopes that their efforts will signal a paradigm shift in the way Multiple Sclerosis (MS) is treated, going beyond small steps forward to provide patients with this crippling illness with life-changing options.
The overall objective includes stopping the disease’s development as well as promoting neuronal regeneration and improving patients’ quality of life. The goal is to significantly enhance each person’s overall condition and give them back the agency to manage their own health journey by providing them the tools they need to regain control of their health and well-being.
The current fundraising success is evidence of the growing trust that people have in Cadenza Bio’s novel approach to treating demyelinating illnesses, such as Multiple Sclerosis (MS). This success highlights the increasing confidence that the company’s approach is receiving, and marks a turning point in the evolution of treatment for these crippling illnesses.
Cadenza Bio has a strong pipeline of ERβ-targeted drugs and a well-defined strategic goal, which will help it fulfil the unmet requirements of patients with these debilitating conditions.
